Chronic Myeloid Leukemia

Common Name(s)

Chronic Myeloid Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloid Leukemia" returned 1334 free, full-text research articles on human participants. First 3 results:

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
 

Author(s): Beatriz Felicio Ribeiro, Eliana C M Miranda, Dulcinéia Martins de Albuquerque, Márcia T Delamain, Gislaine Oliveira-Duarte, Maria Helena Almeida, Bruna Vergílio, Rosana Antunes da Silveira, Vagner Oliveira-Duarte, Irene Lorand-Metze, Carmino A De Souza, Katia B B Pagnano

Journal: Clinics (Sao Paulo). 2015 Aug;70(8):550-5.

 

To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib.

Last Updated: 7 Aug 2015

Go To URL
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
 

Author(s): T P Hughes, G Saglio, A Quintás-Cardama, M J Mauro, D-W Kim, J H Lipton, M B Bradley-Garelik, J Ukropec, A Hochhaus

Journal: Leukemia. 2015 Sep;29(9):1832-8.

 

BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased ...

Last Updated: 2 Sep 2015

Go To URL
Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.
 

Author(s): Monica Napoleão Fortes Rego, Konradin Metze, Irene Lorand-Metze

Journal: Clinics (Sao Paulo). 2015 May;70(5):322-5.

 

In Brazil, imatinib mesylate is supplied as the first-line therapy for chronic myeloid leukemia in the chronic phase through the public universal healthcare program, Sistema Único de Saúde (SUS). We studied the socio-demographic factors that influenced therapy success in a population ...

Last Updated: 4 Jun 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloid Leukemia" returned 156 free, full-text review articles on human participants. First 3 results:

Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature.
 

Author(s): L Wang, F Du, H-M Zhang, H-X Wang

Journal: Braz. J. Med. Biol. Res.. 2015 Jul;48(7):583-7.

 

We report the case of a father and son diagnosed with atypical chronic myeloid leukemia (aCML). Both patients harbored SETBP1 mutations, which are present in 24.3% of aCML patients. Moreover, both shared the variant encoding p.Pro737His, but the aCML severity was greater in the son ...

Last Updated: 9 Jul 2015

Go To URL
Hematopoietic cell transplantation in chronic myeloid leukemia in the age of tyrosine kinase inhibitors.
 

Author(s): Edward A Copelan, Michael R Grunwald, Nilanjan Ghosh, Dragos Plesca, Jigar Trivedi, Belinda R Avalos

Journal: Discov Med. 2015 Mar;19(104):213-8.

 

The development and widespread use of tyrosine kinase inhibitors (TKIs) has relegated the use of hematopoietic cell transplant (HCT), in most countries, to chronic myeloid leukemia (CML) patients who fail or are intolerant to TKIs. Its long-term cost effectiveness compared to TKIs, ...

Last Updated: 1 Apr 2015

Go To URL
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
 

Author(s): Rena M Conti, William V Padula, Richard A Larson

Journal: Ann. Hematol.. 2015 Apr;94 Suppl 2():S249-57.

 

Imatinib is an oral tyrosine kinase inhibitor and considered to be the most successful targeted anti-cancer agent yet developed given its substantial efficacy in treating chronic myeloid leukemia (CML) and other malignant diseases. In the USA and the European Union (EU), Novartis' ...

Last Updated: 27 Mar 2015

Go To URL
 
 
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
 

Status: Recruiting

Condition Summary: Chronic Phase Philadelphia Positive; BCR-ABL Positive; Chronic Myeloid Leukaemia

 

Last Updated: 22 Feb 2015

Go to URL
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 26 May 2015

Go to URL
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 18 May 2013

Go to URL